Despite the development of targeted agents for the treatment of HR-positive and HER2-positive breast cancers, cytotoxic chemotherapy remains integral to the treatment of breast cancer, particularly triple-negative breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.